Novel Biomarkers of Renal Dysfunction and Congestion in Heart Failure

2Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

Heart failure is a major public health problem and, despite the constantly emerging, new, effective treatments, it remains a leading cause of morbidity and mortality. Reliable tools for early diagnosis and risk stratification are crucial in the management of HF. This explains a growing interest in the development of new biomarkers related to various pathophysiological mechanisms of HF. In the course of this review, we focused on the markers of congestion and renal dysfunction in terms of their interference with cardiovascular homeostasis. Congestion is a hallmark feature of heart failure, contributing to symptoms, morbidity, and hospitalizations of patients with HF and has, therefore, become a therapeutic target in AHF. On the other hand, impaired renal function by altering the volume status contributes to the development and progression of HF and serves as a marker of an adverse clinical outcome. Early detection of congestion and an adequate assessment of renal status are essential for the prompt administration of patient‐tailored therapy. This review provides an insight into recent advances in the field of HF biomarkers that could be potentially implemented in diagnosis and risk stratification of patients with HF.

Cite

CITATION STYLE

APA

Zdanowicz, A., Urban, S., Ponikowska, B., Iwanek, G., Zymliński, R., Ponikowski, P., & Biegus, J. (2022). Novel Biomarkers of Renal Dysfunction and Congestion in Heart Failure. Journal of Personalized Medicine, 12(6). https://doi.org/10.3390/jpm12060898

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free